» Articles » PMID: 37583897

Pan-cancer and Single-cell Analysis Reveal the Prognostic Value and Immune Response of NQO1

Overview
Specialty Cell Biology
Date 2023 Aug 16
PMID 37583897
Authors
Affiliations
Soon will be listed here.
Abstract

Overexpression of the gene has been linked with tumor progression, aggressiveness, drug resistance, and poor patient prognosis. Most research has described the biological function of the in certain types and limited samples, but a comprehensive understanding of the 's function and clinical importance at the pan-cancer level is scarce. More research is needed to understand the role of in tumor infiltration, and immune checkpoint inhibitors in various cancers are needed. The expression data for 33 types of pan-cancer and their association with the prognosis, pathologic stage, gender, immune cell infiltration, the tumor mutation burden, microsatellite instability, immune checkpoints, enrichment pathways, and the half-maximal inhibitory concentration (IC50) were downloaded from public databases. Our findings indicate that the gene was significantly upregulated in most cancer types. The Cox regression analysis showed that overexpression of the gene was related to poor OS in Glioma, uveal melanoma, head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma, and adrenocortical carcinoma. mRNA expression positively correlated with infiltrating immune cells and checkpoint molecule levels. The single-cell analysis revealed a potential relationship between the mRNA expression levels and the infiltration of immune cells and stromal cells in bladder urothelial carcinoma, invasive breast carcinoma, and colorectal cancer. Conversely, a negative association was noted between various drugs (17-AAG, Lapatinib, Trametinib, PD-0325901) and the mRNA expression levels. NQO1 expression was significantly associated with prognosis, immune infiltrates, and drug resistance in multiple cancer types. The inhibition of the -dependent signaling pathways may provide a promising strategy for developing new cancer-targeted therapies.

Citing Articles

SP600125, a selective JNK inhibitor, is a potent inhibitor of NAD(P)H: quinone oxidoreductase 1 (NQO1).

Zhong B, Zhang Y, Zheng H, Chen Q, Lu H, Chen X Acta Pharmacol Sin. 2024; .

PMID: 39587283 DOI: 10.1038/s41401-024-01418-1.


Single cell RNA-sequencing in uveal melanoma: advances in heterogeneity, tumor microenvironment and immunotherapy.

Tang S, Zhang Y, Huang S, Zhu T, Huang X Front Immunol. 2024; 15:1427348.

PMID: 38966635 PMC: 11222395. DOI: 10.3389/fimmu.2024.1427348.

References
1.
Sheth S, Farquhar D, Schrank T, Stepp W, Mazul A, Hayward M . Correlation of alterations in the pathway with radiation failure in larynx squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2021; 6(4):699-707. PMC: 8356873. DOI: 10.1002/lio2.588. View

2.
Fan J, Ye J, Kamphorst J, Shlomi T, Thompson C, Rabinowitz J . Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014; 510(7504):298-302. PMC: 4104482. DOI: 10.1038/nature13236. View

3.
Liu Z, He Q, Liu Y, Zhang Y, Cui M, Peng H . Hsa_circ_0005915 promotes N,N-dimethylformamide-induced oxidative stress in HL-7702 cells through NRF2/ARE axis. Toxicology. 2021; 458:152838. DOI: 10.1016/j.tox.2021.152838. View

4.
Kim S . Oxidative stress and gender disparity in cancer. Free Radic Res. 2022; 56(1):90-105. DOI: 10.1080/10715762.2022.2038789. View

5.
Hadley K, Hendricks D . Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. BMC Cancer. 2014; 14:334. PMC: 4032580. DOI: 10.1186/1471-2407-14-334. View